SOPHiA GENETICS SA

SOPH Healthcare Health Information Services

SOPHiA GENETICS SA’s revenue for fiscal 2025 (year ended December 2025) was $77.3 million, up 18.6% from fiscal 2024.

Revenue
+24.7%
EPS
+21.0%
Free cash flow
−1.87%
Total debt
+1.19%

Quarter to September 2026, against a year earlier

7.09 0.47 +7.10%
Market cap
$563.6M
P/E
0.0×
Fwd P/E
−8.1×
Dividend yield
—
F-score
2/9
Altman Z
−3.43
Beneish M
−3.30
Dividend safety
n/a

SOPHiA GENETICS SA (SOPH) P/E ratio

Alert me on P/E ratio

SOPHiA GENETICS SA has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —

Quarterly newest first

Period P/E ratio Change
Sep 2026 0.0× —
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
23 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

P/E ratio against peers

Company P/E ratio
SOPH SOPHiA GENETICS SA n/m
EVH Evolent Health, Inc compare n/m
CARL Carlsmed, Inc. compare n/m
CTEV Claritev Corporation compare n/m
HSTM HealthStream, Inc. compare 42.0×
GDRX GoodRx Holdings, Inc. compare 65.7×
PHR Phreesia, Inc. compare 74.4×
NRC National Research Corporation compare 87.6×
OMDA Omada Health, Inc. compare 267×
Health Information Services industry median 42.0×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on SOPH